Literature DB >> 10405110

Fluoxetine-maintained obese humans: effect on food intake and body weight.

A S Ward1, S D Comer, M Haney, M W Fischman, R W Foltin.   

Abstract

The effects of fluoxetine on food intake, body weight, and mood of obese individuals was examined in a 16-week inpatient/outpatient study. Six male and eight female obese volunteers began the study (four male and five females completed all phases of the study). They lived in a residential laboratory during three one-week inpatient periods separated by a 5-week and an 8-week outpatient period. Following an initial 4-day placebo baseline, participants were maintained on fluoxetine (60 mg/day) for the remainder of the study. Food intake parameters (total daily energy intake, macronutrient intake, mean number of eating bouts, interbout interval), body weight, subjective effects, and task performance were measured several times during the day during inpatient periods; food intake questionnaires were completed daily during the outpatient periods. Fluoxetine significantly reduced daily energy intake derived from fat, carbohydrate, and protein by decreasing the mean number of eating bouts per day throughout the study. No other food intake parameter was affected. Body weight was significantly reduced after 7 weeks, but not after 16 weeks of daily fluoxetine administration. These results indicate that fluoxetine reduced food intake for at least 16 weeks in nondepressed obese individuals without specifically affecting carbohydrate intake. Weight that was lost during the first few weeks of daily fluoxetine administration was subsequently regained even though food intake remained reduced. Therefore, fluoxetine maintenance does not appear promising as a sole long-term therapy for obesity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10405110     DOI: 10.1016/s0031-9384(99)00020-7

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  9 in total

Review 1.  Serotonergic drugs : effects on appetite expression and use for the treatment of obesity.

Authors:  Jason C G Halford; Joanne A Harrold; Emma J Boyland; Clare L Lawton; John E Blundell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Citalopram improves metabolic risk factors among high hostile adults: results of a placebo-controlled intervention.

Authors:  Thomas W Kamarck; Matthew F Muldoon; Stephen B Manuck; Roger F Haskett; Jeewon Cheong; Janine D Flory; Elizabeth Vella
Journal:  Psychoneuroendocrinology       Date:  2011-02-08       Impact factor: 4.905

Review 3.  What pharmacological interventions are effective in binge-eating disorder? Insights from a critical evaluation of the evidence from clinical trials.

Authors:  David J Heal; Jane Gosden
Journal:  Int J Obes (Lond)       Date:  2022-01-07       Impact factor: 5.551

4.  Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice.

Authors:  Lin Jia; Yuan-Yuan Shang; Yu-Yuan Li
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

5.  Serum serotonin levels and bone in rheumatoid arthritis patients.

Authors:  Miguel Bernardes; Tiago Vieira; Raquel Lucas; Jorge Pereira; Lúcia Costa; Francisco Simões-Ventura; Maria João Martins
Journal:  Rheumatol Int       Date:  2017-10-09       Impact factor: 2.631

6.  Relation of serum serotonin levels to bone density and structural parameters in women.

Authors:  Ulrike I Mödder; Sara J Achenbach; Shreyasee Amin; B Lawrence Riggs; L Joseph Melton; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

Review 7.  Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior.

Authors:  Ewa Bojanowska; Joanna Ciosek
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

8.  On the Drive Specificity of Freudian Drives for the Generation of SEEKING Activities: The Importance of the Underestimated Imperative Motor Factor.

Authors:  Michael Kirsch; Wolfgang Mertens
Journal:  Front Psychol       Date:  2018-05-03

Review 9.  Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology.

Authors:  David J Heal; Sharon L Smith
Journal:  J Psychopharmacol       Date:  2021-07-28       Impact factor: 4.562

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.